Daiichi Sankyo Company, Limited is a prominent global pharmaceutical firm based in Japan, recognized as the second-largest pharmaceutical company in the country. Established on September 28, 2005, through the merger of two century-old companies—Sankyo Company, Limited and Daiichi Pharmaceutical Company, Limited—it has a rich history in the pharmaceutical industry. ## Company Overview - **Headquarters**: Tokyo, Japan - **Revenue**: Approximately JPY 1,278 billion (2022) [2]. - **Global Presence**: Operates through subsidiaries in the United States (Daiichi Sankyo Inc.) and Europe (Daiichi Sankyo Europe GmbH), with significant operations in various countries [2][4]. ## Key Products and Innovations Daiichi Sankyo is known for its innovative drug development, particularly in oncology. One of its notable products is **Enhertu**, an antibody-drug conjugate developed in collaboration with AstraZeneca for cancer treatment. The drug received FDA approval in January 2020 and significantly boosted the company's market value [2]. Other important products include: - **Quizartinib**: A treatment for acute myeloid leukemia. - **Injectafer**: An iron replacement therapy for patients with iron deficiency anemia [4]. ## Acquisitions and Growth The company has expanded its portfolio through strategic acquisitions: - In 2006, it acquired Zepharma, the OTC drugs unit of Astellas Pharma. - It took a majority stake in Indian generic drug maker Ranbaxy in 2008. - The purchase of Plexxikon in 2011 added to its oncology pipeline [2]. ## Challenges and Controversies In 2015, Daiichi Sankyo faced scrutiny due to allegations of improper payments to physicians as part of a speaker fee program. This led to a corporate integrity agreement aimed at monitoring its practices [2]. ## Conclusion Daiichi Sankyo continues to be a key player in the global pharmaceutical landscape, focusing on innovative therapies while navigating challenges related to compliance and market competition. Its commitment to research and development positions it well for future growth in the healthcare sector. Citations: [1] https://www.daiichisankyo.com [2] https://en.wikipedia.org/wiki/Daiichi_Sankyo [3] https://ko.wikipedia.org/wiki/%EB%8B%A4%EC%9D%B4%EC%9D%B4%EC%B0%8C%EC%82%B0%EC%BF%84 [4] https://www.drugs.com/manufacturer/daiichi-sankyo-inc-165.html [5] https://www.daiichisankyo.co.kr [6] https://www.daiichi-sankyo.eu